Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Response to Aflibercept Therapy in Three Types of Choroidal Neovascular Membrane in Neovascular Age-Related Macular Degeneration: Real-Life Evidence in the Czech Republic

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F19%3AN0000146" target="_blank" >RIV/00064173:_____/19:N0000146 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00216208:11120/19:43918460 RIV/00216208:11150/19:10395539 RIV/00179906:_____/19:10395539 RIV/00843989:_____/19:E0107862 RIV/61988987:17110/19:A2102735

  • Výsledek na webu

    <a href="https://doi.org/10.1155/2019/2635689" target="_blank" >https://doi.org/10.1155/2019/2635689</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1155/2019/2635689" target="_blank" >10.1155/2019/2635689</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Response to Aflibercept Therapy in Three Types of Choroidal Neovascular Membrane in Neovascular Age-Related Macular Degeneration: Real-Life Evidence in the Czech Republic

  • Popis výsledku v původním jazyce

    Purpose. To present a cohort of treatment-naive patients with the neovascular form of age-related macular degeneration (nAMD) treated with aflibercept in a fixed regimen and evaluate the treatment response of three types of choroidal neovascular membrane (CNV)-occult (Type 1), classic (Type 2), and minimally classic (Type 4). Methods. This was a multicentre, prospective, observational consecutive case series study. Patients diagnosed with three types of CNV of nAMD were treated in a fixed regimen (3 injections every 4weeks, and then injections at 8week intervals). The follow-up period was 48weeks. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and spectral-domain optical coherence tomography (OCT). The measurements were taken at the baseline and then at 16, 32, and 48weeks. Results. The treatment-naive group was composed of 135 eyes of 135 patients in the study. 61 eyes had Type 1 lesions of CNV, 50 eyes had Type 2 lesions, and 24 eyes had Type 4 lesions. Mean baseline BCVA +/- SD for Type 1 lesions was 56.1 +/- 10.8 ETDRS letters, and then 62.2 +/- 12.9 letters, 61.2 +/- 13.7 letters, and 62.8 +/- 15.1 letters at 16, 32, and 48weeks, respectively. Mean baseline CRT +/- SD for Type 1 lesions was 442.4 +/- 194.9 mu m, and then 302.5 +/- 144.4 mu m, 299.7 +/- 128.5 mu m, and 277.7 +/- 106.5 mu m at 16, 32, and 48weeks, respectively. Mean baseline BCVA +/- SD for Type 2 lesions was 55.6 +/- 9.9 ETDRS letters, and then 62.5 +/- 11.1 letters, 60.7 +/- 13.0 letters, and 62.5 +/- 14.2 letters at 16, 32, and 48weeks, respectively. Mean baseline CRT +/- SD. For Type 4 lesions mean baseline BCVA +/- SD was 56.7 +/- 9.0 ETDRS letters, and then 59.1 +/- 10.6 letters, 59.5 +/- 11.4 letters, and 59.2 +/- 12.6 letters at 16, 32, and 48 weeks respectively. Mean baseline CRT +/- SD for Type 4 lesions was 492.1 +/- 187.0 mu m, and then 333.3 +/- 137.5 mu m, 354.4 +/- 175.0 mu m, and 326.7 +/- 122.4 mu m at 16, 32, and 48 weeks respectively. All these changes were statistically significant (p<0.005). Conclusions. The primary outcome of our study is that the treatment with aflibercept in nAMD patients led to statistically significant improvement in BCVA and to a decrease in CRT throughout the follow-up period in both occult and classic types of CNV. The minimally classic type of CNV demonstrated a poorer functional and anatomical response to treatment.

  • Název v anglickém jazyce

    Response to Aflibercept Therapy in Three Types of Choroidal Neovascular Membrane in Neovascular Age-Related Macular Degeneration: Real-Life Evidence in the Czech Republic

  • Popis výsledku anglicky

    Purpose. To present a cohort of treatment-naive patients with the neovascular form of age-related macular degeneration (nAMD) treated with aflibercept in a fixed regimen and evaluate the treatment response of three types of choroidal neovascular membrane (CNV)-occult (Type 1), classic (Type 2), and minimally classic (Type 4). Methods. This was a multicentre, prospective, observational consecutive case series study. Patients diagnosed with three types of CNV of nAMD were treated in a fixed regimen (3 injections every 4weeks, and then injections at 8week intervals). The follow-up period was 48weeks. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and spectral-domain optical coherence tomography (OCT). The measurements were taken at the baseline and then at 16, 32, and 48weeks. Results. The treatment-naive group was composed of 135 eyes of 135 patients in the study. 61 eyes had Type 1 lesions of CNV, 50 eyes had Type 2 lesions, and 24 eyes had Type 4 lesions. Mean baseline BCVA +/- SD for Type 1 lesions was 56.1 +/- 10.8 ETDRS letters, and then 62.2 +/- 12.9 letters, 61.2 +/- 13.7 letters, and 62.8 +/- 15.1 letters at 16, 32, and 48weeks, respectively. Mean baseline CRT +/- SD for Type 1 lesions was 442.4 +/- 194.9 mu m, and then 302.5 +/- 144.4 mu m, 299.7 +/- 128.5 mu m, and 277.7 +/- 106.5 mu m at 16, 32, and 48weeks, respectively. Mean baseline BCVA +/- SD for Type 2 lesions was 55.6 +/- 9.9 ETDRS letters, and then 62.5 +/- 11.1 letters, 60.7 +/- 13.0 letters, and 62.5 +/- 14.2 letters at 16, 32, and 48weeks, respectively. Mean baseline CRT +/- SD. For Type 4 lesions mean baseline BCVA +/- SD was 56.7 +/- 9.0 ETDRS letters, and then 59.1 +/- 10.6 letters, 59.5 +/- 11.4 letters, and 59.2 +/- 12.6 letters at 16, 32, and 48 weeks respectively. Mean baseline CRT +/- SD for Type 4 lesions was 492.1 +/- 187.0 mu m, and then 333.3 +/- 137.5 mu m, 354.4 +/- 175.0 mu m, and 326.7 +/- 122.4 mu m at 16, 32, and 48 weeks respectively. All these changes were statistically significant (p<0.005). Conclusions. The primary outcome of our study is that the treatment with aflibercept in nAMD patients led to statistically significant improvement in BCVA and to a decrease in CRT throughout the follow-up period in both occult and classic types of CNV. The minimally classic type of CNV demonstrated a poorer functional and anatomical response to treatment.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30207 - Ophthalmology

Návaznosti výsledku

  • Projekt

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2019

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Journal of Ophthalmology

  • ISSN

    2090-004X

  • e-ISSN

    2090-0058

  • Svazek periodika

    2019

  • Číslo periodika v rámci svazku

    June

  • Stát vydavatele periodika

    US - Spojené státy americké

  • Počet stran výsledku

    6

  • Strana od-do

    Article 2635689

  • Kód UT WoS článku

    000474532800001

  • EID výsledku v databázi Scopus

    2-s2.0-85068866199